Health‐associated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with high‐performance liquid chromatography

References

• Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–5
   PubMed Web of Science ®Google Scholar
• Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109–42
   PubMed Web of Science ®Google Scholar
• Valkonen V. P., Tuomainen T. P., Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med 2005; 10 Suppl 1: S45–8
   Web of Science ®Google Scholar
• Schulze F., Lenzen H., Hanefeld C., Bartling A., Osterziel K. J., Goudeva L., et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination Investigating the Influence of ADMA Concentration (CARDIAC) Study. Am Heart J 2006; 152: 493 e1‐8
   PubMed Web of Science ®Google Scholar
• Kielstein J. T., Boger R. H., Bode‐Boger S. M., Schaffer J., Barbey M., Koch K. M., et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end‐stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594–600
   PubMed Web of Science ®Google Scholar
• Zoccali C., Bode‐Boger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end‐stage renal disease: a prospective study. Lancet 2001; 358: 2113–17
   PubMed Web of Science ®Google Scholar
• Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449–55
   PubMed Web of Science ®Google Scholar
• Clarke S. Protein methylation. Curr Opin Cell Biol 1993; 5: 977–83
   PubMed Web of Science ®Google Scholar
• Teerlink T. ADMA metabolism and clearance. Vasc Med 2005; 10 Suppl 1: S73–81
   Web of Science ®Google Scholar
• Leiper J. M. The DDAH‐ADMA‐NOS pathway. Ther Drug Monit 2005; 27: 744–6
   PubMed Web of Science ®Google Scholar
• Vallance P., Leone A., Calver A., Collier J., Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 Suppl 12: S60–2
   Web of Science ®Google Scholar
• Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455–9
   PubMed Web of Science ®Google Scholar
• Nijveldt R. J., Van Leeuwen P. A., Van Guldener C., Stehouwer C. D., Rauwerda J. A., Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 2002; 17: 1999–2002
   PubMed Web of Science ®Google Scholar
• Closs E. I., Basha F. Z., Habermeier A., Forstermann U. Interference of L‐arginine analogues with L‐arginine transport mediated by the y+ carrier hCAT‐2B. Nitric Oxide 1997; 1: 65–73
   PubMed Web of Science ®Google Scholar
• Solberg H. E. Establishment and use of reference values. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, C. A Burtis, E. R Ashwood, D. E Bruns. Elsevier Saunders, St. Louis, Mo. 2006; 425–48
   Google Scholar
• Horowitz J. D., Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: Methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci 2006 Oct 10
   PubMed Web of Science ®Google Scholar
• Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn E., Boger R. H. Determination of a reference value for N(G), N(G)‐dimethyl‐L‐arginine in 500 subjects. Eur J Clin Invest 2005; 35: 622–6
   PubMed Web of Science ®Google Scholar
• Valtonen P., Karppi J., Nyyssonen K., Valkonen V. P., Halonen T., Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 828: 97–102
   PubMed Web of Science ®Google Scholar
• The Norwegian Directorate for Health and Social Affairs. 2004, Guidelines for the service of transfusion in Norway
   Google Scholar
• Beltowski J., Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006; 58: 159–78
   PubMed Web of Science ®Google Scholar
• Teerlink T., Nijveldt R. J., de Jong S., van Leeuwen P. A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high‐performance liquid chromatography. Anal Biochem 2002; 303: 131–7
   PubMed Web of Science ®Google Scholar
• Levey A. S., Bosch J. P., Lewis J. B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–70
   PubMed Web of Science ®Google Scholar
• Solberg H. E. The IFCC recommendation on estimation of reference intervals. The RefVal program. Clin Chem Lab Med 2004; 42: 710–14
   PubMed Web of Science ®Google Scholar
• Linnet K. Nonparametric estimation of reference intervals by simple and bootstrap‐based procedures. Clin Chem 2000; 46: 867–9
   PubMed Web of Science ®Google Scholar
• Lahti A., Petersen P. H., Boyd J. C., Rustad P., Laake P., Solberg H. E. Partitioning of nongaussian‐distributed biochemical reference data into subgroups. Clin Chem 2004; 50: 891–900
   PubMed Web of Science ®Google Scholar
• Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005; 43: 1130–8
   PubMed Web of Science ®Google Scholar
• Miyazaki H., Matsuoka H., Cooke J. P., Usui M., Ueda S., Okuda S., et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141–6
   PubMed Web of Science ®Google Scholar
• Martens‐Lobenhoffer J., Bode‐Boger S. M. Chromatographic‐mass spectrometric methods for the quantification of l‐arginine and its methylated metabolites in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2006
   PubMed Web of Science ®Google Scholar
• Blake J. Menopause: evidence‐based practice. Best Pract Res Clin Obstet Gynaecol 2006 Dec; 20((6))799–839
   PubMed Web of Science ®Google Scholar
• Teerlink T., Neele S. J., de Jong S., Netelenbos J. C., Stehouwer C. D. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) 2003; 105: 67–71
   PubMed Web of Science ®Google Scholar
• Holden D. P., Cartwright J. E., Nussey S. S., Whitley G. S. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 2003; 108: 1575–80
   PubMed Web of Science ®Google Scholar
• Kielstein J. T., Salpeter S. R., Bode‐Boeger S. M., Cooke J. P., Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function – a meta‐analysis. Nephrol Dial Transpl 2006; 21: 2446–51
   PubMed Web of Science ®Google Scholar
• Wang J., Sim A. S., Wang X. L., Wilcken D. E. L‐arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cell Mol Life Sci 2006 Dec; 63((23))2838–46
   PubMed Web of Science ®Google Scholar